Multi‐omics analysis reveals drivers of loss of β ‐cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study
Diabetes/Metabolism Research and Reviews · 2024
DOI: 10.1002/dmrr.3833 ↗At a glance
Multizentrische Studie in Diabetes/Metabolism Research and Reviews, 2024. Written by Jose Juan Almagro Armenteros and 32 co-authors. Institution: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Major MEDLINE topics: Diabetes Mellitus, Type 1, Insulin-Secreting Cells. Cited 16 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Innovative Medicine Initiative 2 Joint Undertaking, European Federation of Pharmaceutical Industries and Associations, European Union's Horizon 2020 research and innovation program.
Topics: Diabetes mellitus
Abstract (original language)
Aims
Heterogeneity in the rate of β ‐cell loss in newly diagnosed type 1 diabetes patients is poorly understood and creates a barrier to designing and interpreting disease‐modifying clinical trials. Integrative analyses of baseline multi‐omics data obtained after the diagnosis of type 1 diabetes may provide mechanistic insight into the diverse rates of disease progression after type 1 diabetes diagnosis.
Methods
We collected samples in a pan‐European consortium that enabled the concerted analysis of five different omics modalities in data from 97 newly diagnosed patients. In this study, we used Multi‐Omics Factor Analysis to identify molecular signatures correlating with post‐diagnosis decline in β ‐cell mass measured as fasting C‐peptide.
Results
Two molecular signatures were significantly correlated with fasting C‐peptide levels. One signature showed a correlation to neutrophil degranulation, cytokine signalling, lymphoid and non‐lymphoid cell interactions and G‐protein coupled receptor signalling events that were inversely associated with a rapid decline in β ‐cell function. The second signature was related to translation and viral infection was inversely associated with change in β ‐cell function. In addition, the immunomics data revealed a Natural Killer cell signature associated with rapid β ‐cell decline.
Conclusions
Features that differ between individuals with slow and rapid decline in β ‐cell mass could be valuable in staging and prediction of the rate of disease progression and thus enable smarter (shorter and smaller) trial designs for disease modifying therapies as well as offering biomarkers of therapeutic effect.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
- InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
- Department of Paediatrics, University of Cambridge, Cambridge, England.
- Steno Diabetes Center Copenhagen, Systems Medicine, Herlev, Denmark.
- Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
ORCID profiles: Christian Holm Johansen, Robert Moulder, Karoliina Hirvonen, Emile Hendricks, Guido Sebastiani, Søren Brunak
Funding
- Innovative Medicine Initiative 2 Joint Undertaking
- European Federation of Pharmaceutical Industries and Associations
- European Union's Horizon 2020 research and innovation program
- Leona M. and Harry B. Helmsley Charitable Trust
- Breakthrough T1D
- JDRF
Cite
APA
Armenteros, J. J. A., Brorsson, C., Johansen, C. H., Banasik, K., Mazzoni, G., Moulder, R., Hirvonen, K., Suomi, T., Rasool, O., Bruggraber, S. F. A., Marcovecchio, M. L., Hendricks, E., Al-Sari, N., Mattila, I., Legido-Quigley, C., Suvitaival, T., Chmura, P. J., Knip, M., Schulte, A. M., …, & INNODIA investigators (2024). Multi‐omics analysis reveals drivers of loss of β ‐cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3833
Vancouver
Armenteros JJA, Brorsson C, Johansen CH, Banasik K, Mazzoni G, Moulder R, et al. Multi‐omics analysis reveals drivers of loss of β ‐cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study. Diabetes/Metabolism Research and Reviews. 2024. doi:10.1002/dmrr.3833
BibTeX
@article{Armenteros2024,
author = {Armenteros, Jose Juan Almagro and Brorsson, Caroline and Johansen, Christian Holm and Banasik, Karina and Mazzoni, Gianluca and Moulder, Robert and Hirvonen, Karoliina and Suomi, Tomi and Rasool, Omid and Bruggraber, Sylvaine F A and Marcovecchio, M Loredana and Hendricks, Emile and Al-Sari, Naba and Mattila, Ismo and Legido-Quigley, Cristina and Suvitaival, Tommi and Chmura, Piotr J and Knip, Mikael and Schulte, Anke M and Lee, Jeong Heon and Sebastiani, Guido and Grieco, Giuseppina Emanuela and Elo, Laura L and Kaur, Simranjeet and Pociot, Flemming and Dotta, Francesco and Tree, Tim and Lahesmaa, Riitta and Overbergh, Lut and Mathieu, Chantal and Peakman, Mark and Brunak, Søren and INNODIA investigators, INNODIA investigators},
title = {Multi‐omics analysis reveals drivers of loss of β ‐cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2024},
doi = {10.1002/dmrr.3833}
}
EUVIMED